[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614362":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":60,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":86,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All participants",null,"Each participant will serve as their own control and will be followed during control and intervention periods of the study",[13],"Behavioral: MedSafer deprescribing opportunity reports, EMPOWER brochures",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BEHAVIORAL","MedSafer deprescribing opportunity reports, EMPOWER brochures","1. Deprescribing opportunity reports: The MedSafer software generates reports by applying embedded \"rules\" to medication lists, reflecting best practice recommendations. Deprescribing \"opportunities\" are classified into high risk (for adverse drug events), intermediate risk (harms must be weighed against benefits), and low risk for harm (but with no added value to continue). Reports include the rationale for deprescribing, tapering instructions, or safer drug alternatives (if relevant), and are provided to clinicians at the point-of-care.\n2. Patient-oriented educational material:\n\n   1. Deprescribing fact sheet (all participants)\n   2. Consumer-facing bilingual 'EMPOWER' educational brochures for specific PIMs (e.g., gabapentinoids, proton pump inhibitors, benzodiazepines) if applicable",[9],[21],{"name":22,"affiliation":23,"role":24},"Arielle Mendel, MD MSc","RI-MUHC\u002FMUHC","PRINCIPAL_INVESTIGATOR",[26,31],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","5149341934","47284","arielle.mendel@mcgill.ca",{"name":32,"role":27,"phone":10,"phoneExt":10,"email":33},"Jeannette Bere, BSc, LPN","jeannette.bere@rimuhc.ca",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Montreal General Hospital, McGill University Health Centre","RECRUITING","Montreal","Quebec","H3G1A4","Canada","CA",{"type":44,"coordinates":45},"Point",[46,47],-73.58781,45.50884,{"lat":47,"lon":46},[50,52,54,55,58],{"name":22,"role":27,"phone":51,"phoneExt":10,"email":30},"514-934-1934",{"name":53,"role":27,"phone":10,"phoneExt":10,"email":33},"Jeannette Bere, BSc",{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"name":56,"role":57,"phone":10,"phoneExt":10,"email":10},"Ines Colmegna, MD","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":10,"phoneExt":10,"email":10},"Emily G McDonald, MD MSc",{"type":24,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Arielle Mendel","Assistant Professor\u002FInvestigator",[64],{"name":65,"class":6},"The Arthritis Society, Canada","100614362","the-rheumsafer-study-improving-medication-appropriateness-in-people-with-rheumatic-conditions-100614362",false,"NCT07278609","The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","Inclusion Criteria:\n\n* Aged ≥60\n* Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)\n* Currently taking ≥5 regular medications and ≥1 PIM\n* Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acute life-threatening illness or life expectancy \\\u003C12 months","ALL","60 Years",{"count":75,"type":76},100,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).\n\nResearchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:\n\n* MedSafer reports provided to treating physicians\n* EMPOWER consumer brochures provided to participants\n\nParticipants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.",[80,81,82,83,84,85],"Rheumatic Diseases","Inflammatory Arthritis","Systemic Lupus Erthematosus (SLE)","Vasculitis","Muskuloskeletal Diseases","Systemic Autoimmune Diseases",[87,88,80,89],"Deprescribing","Potentially inappropriate medications","Polypharmacy","2026-04-27",{"date":92,"type":93},"2026-05-01","ACTUAL",{"date":95,"type":93},"2025-10-29",{"date":97,"type":76},"2028-06-30",{"name":5,"class":6},1]